Lanosterol

Lanosterol

SCHEMBL288191

CC(C)=CCC[C@@H](C)[C@H]1CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CCC(O)C(C)(C)[C@@H]1CC3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 1.00
USP2 O75604 2/20 1.00
ALDH1A1 P00352 2/20 1.00
CYP3A4 P08684 2/20 1.00
ALOX15 P16050 2/20 1.00
CRYAB P02511 2/20 1.00
LMNA P02545 1/20 1.00
PTGES O14684 4/20 0.79
FNTA P49354 1/20 0.74
FNTB P49356 1/20 0.74
CRYAA P02489 1/20 0.71
ACHE P22303 1/20 0.62
MEN1 O00255 1/20 0.61
PLA2G1B P04054 1/20 0.61
DNMT1 P26358 1/20 0.61
BLM P54132 1/20 0.61
KMT2A Q03164 1/20 0.61
ATG4B Q9Y4P1 1/20 0.61
HMGCR P04035 1/20 0.61
PREP P48147 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lanosterol SCHEMBL16994483 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL145834 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL14240642 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL14536063 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL14360758 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL2154745 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL145835 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL1696473 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL19194030 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL21348006 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO claimed
EP-2323666-B1 PHARMACEUTICAL USES OF LANOSTA-8,24-DIEN-3-OLS AMAZONIA FITOMEDICAMENTOS LTDA (BR) 2017-01-04 EP claimed
EP-2523663-A1 PHARMACEUTICAL USE OF MULTICYCLIC COMPOUNDS AS ANTI-AIDS AGENTS Amazonia Fitomedicamentos Ltda (BR) 2012-11-21 EP claimed
US-20120289487-A1 Pharmaceutical Use of Multicyclic Compounds as Anti-Aids Agents AMAZÔNIA FITOMEDICAMENTOS LTDA (BR) 2012-11-15 US claimed
JP-2011529956-A 2011-12-15 JP claimed
WO-2011086424-A1 PHARMACEUTICAL USE OF MULTICYCLIC COMPOUNDS MIXTURES AS CONCOMITANT ANTI-CANCER, ANTI-INFLAMMATORY AND ANTI-PAIN AGENTS AMAZONIA FITOMEDICAMENTOS LTDA (BR) 2011-07-21 WO claimed
WO-2011086423-A1 PHARMACEUTICAL USE OF MULTICYCLIC COMPOUNDS AS ANTI-AIDS AGENTS AMAZONIA FITOMEDICAMENTOS LTDA (BR) 2011-07-21 WO claimed
US-20110136773-A1 Pharmaceutical Uses of Lanosta-8,24-dien-3-ols AMAZONIA FITOMEDICAMENTOS LTDA (BR) 2011-06-09 US claimed
EP-2323666-A1 PHARMACEUTICAL USES OF LANOSTA-8,24-DIEN-3-OLS Amazonia Fitomedicamentos Ltda (BR) 2011-05-25 EP claimed
WO-2010015874-A1 PHARMACEUTICAL USES OF LANOSTA-8,24-DIEN-3-OLS AMAZONIA FITOMEDICAMENTOS LTDA (BR) 2010-02-11 WO claimed
EP-4615821-A1 PARTICLE COMPOSITIONS COMPRISING POLYSARCOSINE LIPID CONJUGATES Calusa Bio, LLC (US) 2025-09-17 EP disclosed
US-20250161327-A1 PREPARATION OF NOVEL TRITERPENE ALCOHOL DERIVATIVES WITH ENHANCED BIOAVAILABILITY FOR CANCER, INFLAMMATION AND PAIN TREATMENT LIVFUL INC. 2025-05-22 US disclosed
US-20250161327-A1 PREPARATION OF NOVEL TRITERPENE ALCOHOL DERIVATIVES WITH ENHANCED BIOAVAILABILITY FOR CANCER, INFLAMMATION AND PAIN TREATMENT LIVFUL INC. 2025-05-22 US disclosed
WO-2025064408-A1 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE THE BROAD INSTITUTE, INC. (US) 2025-03-27 WO disclosed
EP-4476236-A1 PREPARATION OF NOVEL TRITERPENE ALCOHOL DERIVATIVES WITH ENHANCED BIOAVAILABILITY FOR CANCER, INFLAMMATION AND PAIN TREATMENT Livful Inc (US) 2024-12-18 EP disclosed
EP-2219587-A1 STEROL-MODIFIED AMPHIPHILIC LIPIDS The Regents of the University of California (US) 2010-08-25 EP disclosed
WO-2010015875-A1 PROCESS FOR THE PREPARATION OF LANOSTA-8-ENE COMPOU AMAZONIA FITOMEDICAMENTOS LTDA (BR) 2010-02-11 WO disclosed
WO-2010015874-A1 PHARMACEUTICAL USES OF LANOSTA-8,24-DIEN-3-OLS AMAZONIA FITOMEDICAMENTOS LTDA (BR) 2010-02-11 WO disclosed
WO-2010015874-A1 PHARMACEUTICAL USES OF LANOSTA-8,24-DIEN-3-OLS AMAZONIA FITOMEDICAMENTOS LTDA (BR) 2010-02-11 WO disclosed
WO-2009064696-A1 STEROL-MODIFIED AMPHIPHILIC LIPIDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161327-A1 PREPARATION OF NOVEL TRITERPENE ALCOHOL DERIVATIVES WITH ENHANCED BIOAVAILABILITY FOR CANCER, INFLAMMATION AND PAIN TREATMENT PRKCA, DGKA, MAP3K14 MAPT 2317/4885USP2 4700/4885ALDH1A1 3779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.